Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) EBIT: 2018-2021

Historic EBIT for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$126.9 million.

  • Black Diamond Therapeutics' EBIT fell 12.50% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.3 million, marking a year-over-year decrease of 65.79%. This contributed to the annual value of -$126.9 million for FY2021, which is 82.37% down from last year.
  • Latest data reveals that Black Diamond Therapeutics reported EBIT of -$126.9 million as of FY2021, which was down 82.37% from -$69.6 million recorded in FY2020.
  • Black Diamond Therapeutics' EBIT's 5-year high stood at -$8.9 million during FY2018, with a 5-year trough of -$126.9 million in FY2021.
  • Over the past 3 years, Black Diamond Therapeutics' median EBIT value was -$69.6 million (recorded in 2020), while the average stood at -$75.3 million.
  • Data for Black Diamond Therapeutics' EBIT shows a maximum YoY crashed of 229.42% (in 2019) over the last 5 years.
  • Black Diamond Therapeutics' EBIT (Yearly) stood at -$8.9 million in 2018, then slumped by 229.42% to -$29.3 million in 2019, then slumped by 137.18% to -$69.6 million in 2020, then plummeted by 82.37% to -$126.9 million in 2021.